Correlation Between Cadrenal Therapeutics, and Replimune

Can any of the company-specific risk be diversified away by investing in both Cadrenal Therapeutics, and Replimune at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cadrenal Therapeutics, and Replimune into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Cadrenal Therapeutics, Common and Replimune Group, you can compare the effects of market volatilities on Cadrenal Therapeutics, and Replimune and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cadrenal Therapeutics, with a short position of Replimune. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cadrenal Therapeutics, and Replimune.

Diversification Opportunities for Cadrenal Therapeutics, and Replimune

0.4

Correlation Coefficient

Cadrenal Therapeutics,  Replimune

Very weak diversification

The 3 months correlation between Cadrenal and Replimune is 0.4. Overlapping area represents the amount of risk that can be diversified away by holding Cadrenal Therapeutics, Common and Replimune Group in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Replimune Group and Cadrenal Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cadrenal Therapeutics, Common are associated (or correlated) with Replimune. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Replimune Group has no effect on the direction of Cadrenal Therapeutics, i.e., Cadrenal Therapeutics, and Replimune go up and down completely randomly.

Pair Corralation between Cadrenal Therapeutics, and Replimune

Given the investment horizon of 90 days Cadrenal Therapeutics, Common is expected to generate 1.14 times more return on investment than Replimune. However, Cadrenal Therapeutics, is 1.14 times more volatile than Replimune Group. It trades about 0.12 of its potential returns per unit of risk. Replimune Group is currently generating about -0.05 per unit of risk. If you would invest  1,423  in Cadrenal Therapeutics, Common on December 30, 2024 and sell it today you would earn a total of  423.00  from holding Cadrenal Therapeutics, Common or generate 29.73% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Cadrenal Therapeutics, Common  vs.  Replimune Group

Cadrenal Therapeutics,

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Cadrenal Therapeutics, Common are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain forward-looking signals, Cadrenal Therapeutics, exhibited solid returns over the last few months and may actually be approaching a breakup point.

Replimune Group

Risk-Adjusted Performance

Very Weak

Over the last 90 days Replimune Group has generated negative risk-adjusted returns adding no value to investors with long positions. Despite conflicting performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in April 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

Pair Trading with Cadrenal Therapeutics, and Replimune

The main advantage of trading using opposite Cadrenal Therapeutics, and Replimune positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cadrenal Therapeutics, position performs unexpectedly, Replimune can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Replimune will offset losses from the drop in Replimune's long position.

The idea behind Cadrenal Therapeutics, Common and Replimune Group pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.